<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TCU_Taiwan_Modeling_Protein_structure skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TCU Taiwan/Modeling/Protein structure</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="gg"><DIV id="form" style="background-color:rgba(236,236,231,0.6); overflow-x:hidden;overflow-y:hidden; "><TABLE width="100%" border="0" style="background-color: rgba(236,236,231,0.6)"><TBODY><TR><TD><DIV id="c"><LI><DIV id="m1" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Team/Members">Members</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Team/Instructor">Instructors</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Attributions">Attributions</A></DIV></LI></DIV><DIV id="d"><LI><DIV id="m2" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Description">Overview</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Project/Our Design">Antimicrobial Peptides</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Project/Experimental">Signal Peptide</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Project/Reference">Medical Dressing</A></DIV></LI></DIV><DIV id="e"><LI><DIV id="m6" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Basic_Part">Basic Part </A><A href="https://2015.igem.org/Team:TCU_Taiwan/Composite_Part">Composite Part</A></DIV></LI></DIV><DIV id="f"><LI><A href="https://2015.igem.org/Team:TCU_Taiwan/Modeling/Protein structure">Protein structure </A><A href="https://2015.igem.org/Team:TCU_Taiwan/Modeling">Modeling</A></LI></DIV><DIV id="g"><LI><DIV id="m5" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Safety/overview">Overview</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Safety/Laboratory">Laboratory Practices</A></DIV></LI></DIV><DIV id="h"><LI><DIV id="m3" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Result/vitro">Peptides production</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Result/Macro-dilution">Disinfection efficiency</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Result/Peptides">Cell experiments</A></DIV></LI></DIV><DIV id="i"><LI><DIV id="m7" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Practices">Human Practices</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Collaborations">Collaborations</A></DIV></LI></DIV><DIV id="j"><LI><DIV id="m8" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2015.igem.org/Team:TCU_Taiwan/Notebook/Life">Life</A><A href="https://2015.igem.org/Team:TCU_Taiwan/Notebook/Lab">Lab</A></DIV></LI></DIV></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD align="justify"><H1><SPAN style="font-family:Arial Black;"><FONT size="7"><FONT-WEIGHT: 700=""> About our modeling</FONT-WEIGHT:></FONT></SPAN></H1></TD></TR><TR><TD><H1><SPAN style="font-family:Calibri;text-align:left;"><FONT size="5">
To increase efficiency in isolating our AMPs, we introduced a signal peptide upstream of the N-terminal of our AMPs. This signal peptide is obtained from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). When the fusion peptides enter the periplasmic space, peptidase will identify the cleavage site Ala-Gln-Ala and cut at the double Ala between the signal and AMPs. 
To ensure and verify this process, we have attached an Ala at the N-terminal of AMPs. When applying a protein secondary structure prediction software base on the known peptide structure, we can analyze whether the attached Ala may have an effect on the peptide folding process.
</FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD align="left"><H1><SPAN style="font-family:Arial Black;"><FONT size="7"><FONT-WEIGHT: 700=""> Signiferin peptide structure analysis</FONT-WEIGHT:></FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD><H1><SPAN style="font-family:Calibri;text-align:justify;"><FONT size="5">
The first column shows the amino acid sequence that we predict.
The second column shows that AMPs corresponding secondary structure state are still a-helix. 
The third column shows the probability of correct prediction.
</FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD align="left"><H1><SPAN style="font-family:Arial Black;"><FONT size="7"><FONT-WEIGHT: 700=""> Epinicedin-1 pepetide structure analysis</FONT-WEIGHT:></FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD><H1><SPAN style="font-family:Calibri;text-align:justify;"><FONT size="5">
The first column shows the amino acid sequence that we predict.
The second column shows that AMPs corresponding secondary structure state are still a-helix. 
The third column shows the probability of correct prediction.
</FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><DIV id="st1" class="st"><DIV class="inner"><TABLE width="95%" align="center"><TBODY><TR><TD align="center"><H1><SPAN style="font-family:Arial Black;"><FONT size="7"><FONT-WEIGHT: 700=""> Conclusion</FONT-WEIGHT:></FONT></SPAN></H1></TD></TR><TR><TD><H1><SPAN style="font-family:Calibri;text-align:justify;"><FONT size="5">
Through the analysis of the peptide secondary structure and confirmation of the -helix structure, the results show whether Ala is attached to Signiferin or Epinecidin-1, the peptide did not affect the peptide folding process. process.
</FONT></SPAN></H1></TD></TR></TBODY></TABLE></DIV></DIV><TABLE width="100%" border="0" cellspacing="0" cellpadding="0"><TBODY><TR><TD align="center">         </TD></TR></TBODY></TABLE><TABLE width="100%" border="0"><TBODY><TR><TD align="center"><SPAN style="line-height:20px;"><FONT size="2">Contact us</FONT><FONT size="1">tcutaiwan@gmail.com  </FONT><FONT size="1">  No.701, Sec. 3, Zhongyang Rd. Hualien 97004, Taiwan</FONT></SPAN></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></BODY></HTML>